Comparative Pharmacology
Head-to-head clinical analysis: DENTIPATCH versus LIDOCAINE VISCOUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DENTIPATCH versus LIDOCAINE VISCOUS.
DENTIPATCH vs LIDOCAINE VISCOUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Local anesthetic agent that inhibits sodium ion influx into nerve cells, blocking nerve conduction and pain sensation.
Lidocaine is an amide-type local anesthetic that blocks voltage-gated sodium channels (Nav1.7, Nav1.8) in neuronal membranes, inhibiting depolarization and propagation of action potentials, thereby producing local anesthesia. It also has antiarrhythmic properties (class IB) by blocking sodium channels in cardiac myocytes.
Apply one 10 mg/10 cm² transdermal patch to intact skin once daily, typically in the morning; remove after 24 hours and replace with a new patch.
15 mL (300 mg) orally every 3 hours as needed for pain; maximum 8 doses per 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 7–9 hours; clinically, steady-state is achieved after 2–3 days of daily application.
Terminal elimination half-life is 1.5–2 hours (up to 3 hours in hepatic impairment). Clinically, redistribution half-life (~6 min) determines duration of action after short infusions.
Approximately 60% of the dose is excreted renally as unchanged drug and metabolites; the remainder is eliminated via biliary/fecal routes.
Renal excretion of unchanged drug and metabolites accounts for >90% of elimination; <10% biliary/fecal. Metabolites include monoethylglycinexylidide (MEGX) and glycinexylidide (GX).
Category C
Category A/B
Local Anesthetic
Local Anesthetic / Antiarrhythmic (Class Ib)